These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36685697)

  • 1. Licensed liposomal vaccines and adjuvants in the antigen delivery system.
    Krasnopolsky Y; Pylypenko D
    BioTechnologia (Pozn); 2022; 103(4):409-423. PubMed ID: 36685697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Composition and mode of action of adjuvants in licensed viral vaccines].
    Wagner R; Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Apr; 62(4):462-471. PubMed ID: 30830257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal adjuvants for human vaccines.
    Alving CR; Beck Z; Matyas GR; Rao M
    Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
    Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
    Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing liposomal adjuvants for the next generation of vaccines.
    Perrie Y; Crofts F; Devitt A; Griffiths HR; Kastner E; Nadella V
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):85-96. PubMed ID: 26576719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity.
    Richards RL; Alving CR; Wassef NM
    J Pharm Sci; 1996 Dec; 85(12):1286-9. PubMed ID: 8961140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomes as Adjuvants and Vaccine Delivery Systems.
    Tretiakova DS; Vodovozova EL
    Biochem (Mosc) Suppl Ser A Membr Cell Biol; 2022; 16(1):1-20. PubMed ID: 35194485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal presentation of antigens for human vaccines.
    Glück R
    Pharm Biotechnol; 1995; 6():325-45. PubMed ID: 7551224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil.
    Rao M; Alving CR
    Adv Drug Deliv Rev; 2000 Mar; 41(2):171-88. PubMed ID: 10699313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MnO
    Song T; Liao Y; Zuo Q; Liu N; Liu Z
    J Mater Chem B; 2022 May; 10(18):3474-3490. PubMed ID: 35403638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.
    Watson DS; Endsley AN; Huang L
    Vaccine; 2012 Mar; 30(13):2256-72. PubMed ID: 22306376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome Formulations as Adjuvants for Vaccines.
    Rao M; Peachman KK; Alving CR
    Curr Top Microbiol Immunol; 2021; 433():1-28. PubMed ID: 33165871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal adjuvant development for leishmaniasis vaccines.
    Askarizadeh A; Jaafari MR; Khamesipour A; Badiee A
    Ther Adv Vaccines; 2017 Aug; 5(4-5):85-101. PubMed ID: 29201374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
    Del Giudice G; Rappuoli R; Didierlaurent AM
    Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant and antigen delivery properties of virosomes.
    Glück R; Burri KG; Metcalfe I
    Curr Drug Deliv; 2005 Oct; 2(4):395-400. PubMed ID: 16305442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines.
    Nijen Twilhaar MK; Czentner L; van Nostrum CF; Storm G; den Haan JMM
    Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34202919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.
    Chatzikleanthous D; O'Hagan DT; Adamo R
    Mol Pharm; 2021 Aug; 18(8):2867-2888. PubMed ID: 34264684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvants for pandemic influenza vaccines.
    Atmar RL; Keitel WA
    Curr Top Microbiol Immunol; 2009; 333():323-44. PubMed ID: 19768413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.